Protective Effect of Boswellia Serrata Resin Extract Against Acetaminophen-Induced Subclinical Hepatic Injury in Rats

bashaer K Hameed

doi:10.26629/uzjns.2026.05

PDF

Published: Apr 22, 2026

DOI: https://doi.org/10.26629/uzjns.2026.05

Keywords:

Boswellia serrata, acetaminophen, hepatotoxicity, nephrotoxicity, oxidative stress.

bashaer K Hameed

Department of Biology, College of science, University of Tikrit, Tikrit, Iraq

https://orcid.org/0009-0006-2995-2007

Abstract

The analgesic and antipyretic effect of acetaminophen has made it one of the most widely used drugs in the world; however, acetaminophen overdose causes significant hepatic injury and compromises renal function. This study aimed to evaluate the protective effect of Boswellia serrata resin extract against acetaminophen-induced injury in rats. This was assessed by measuring biochemical and oxidative stress markers, as well as histopathological changes across all groups to provide both direct and indirect evidence of the protective effect of Boswellia serrata against hepatotoxicity and nephrotoxicity caused by acetaminophen. Acetaminophen administration increased serum ALT, AST, ALP, bilirubin, creatinine, and urea levels, elevated malondialdehyde, and reduced levels of glutathione, superoxide dismutase, and catalase levels in liver and kidney tissues. Histopathological examination showed that acetaminophen induced centrilobular hepatic injury and renal tubular injury. Treatment with Boswellia serrata attenuated these biochemical, oxidative, and histopathological alterations in a dose-dependent manner, with the higher dose providing greater protection. These findings indicate that Boswellia serrata resin extract exerts hepatoprotective and reno-protective effects against acetaminophen-induced injury, likely through antioxidant and anti-inflammatory mechanisms.

How to Cite

[1]

bashaer K. Hameed, “Protective Effect of Boswellia Serrata Resin Extract Against Acetaminophen-Induced Subclinical Hepatic Injury in Rats”, UZJNS, vol. 3, no. 1, pp. 42–51, Apr. 2026.

Issue

Vol. 3 No. 1 (2026): Univ Zawia J Nat Sci

Section

Zoology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format.
Adapt — remix, transform, and build upon the material.

Under the following terms:

Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

References

[1] A. M. Larson, "Acetaminophen hepatotoxicity," Clin. Liver Dis., vol. 11, no. 3, pp. 525–548, Aug. 2007, doi: 10.1016/j.cld.2007.06.006.

[2] S. D. Nelson, "Molecular mechanisms of the hepatotoxicity caused by acetaminophen," Semin. Liver Dis., vol. 10, no. 4, pp. 267–278, Nov. 1990, doi: 10.1055/s-2008-1040482.

[3] A. Ramachandran and H. Jaeschke, "Mechanisms of acetaminophen hepatotoxicity and their translation to the human pathophysiology," J. Clin. Transl. Res., vol. 3, Suppl. 1, pp. 157–169, 2017, doi: 10.18053/jctres. 03.2017s1.002.

[4] K. Du, A. Ramachandran, and H. Jaeschke, "Oxidative stress during acetaminophen hepatotoxicity: sources, pathophysiological role and therapeutic potential," Redox Biol., vol. 10, pp. 148–156, Dec. 2016, doi: 10.1016/j.redox.2016.10.001.

[5] M. R. McGill, C. D. Williams, Y. Xie, A. Ramachandran, and H. Jaeschke, "Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity," Toxicol. Appl. Pharmacol., vol. 264, no. 3, pp. 387–394, Nov. 2012, doi: 10.1016/j.taap.2012.08.015.

[6] Y. Xie, M. R. McGill, K. Dorko, S. C. Kumer, T. M. Schmitt, J. Forster, and H. Jaeschke, "Mechanisms of acetaminophen-induced cell death in primary human hepatocytes," Toxicol. Appl. Pharmacol., vol. 279, no. 3, pp. 266–274, Sep. 2014, doi: 10.1016/j.taap.2014.05.010.

[7] A. Ramachandran and H. Jaeschke, "Acetaminophen hepatotoxicity," Semin. Liver Dis., vol. 39, no. 2, pp. 221–234, May 2019, doi: 10.1055/s-0039-1679919.

[8] H. Jaeschke, O. B. Adelusi, J. Y. Akakpo, N. T. Nguyen, G. Sanchez-Guerrero, D. S. Umbaugh, W.-X. Ding, and A. Ramachandran, "Recommendations for the use of the acetaminophen hepatotoxicity model for mechanistic studies and how to avoid common pitfalls," Acta Pharm. Sin. B, vol. 11, no. 12, pp. 3740–3755, Dec. 2021, doi: 10.1016/j.apsb.2021.09.023.

[9] A. Ramachandran and H. Jaeschke, "Oxidant stress and acetaminophen hepatotoxicity: mechanism-based drug development," Antioxid. Redox Signal, vol. 35, no. 9, pp. 718–733, Sep. 2021, doi: 10.1089/ars.2021.0102.

[10] H. Jaeschke and A. Ramachandran, "Mechanisms and pathophysiological significance of sterile inflammation during acetaminophen hepatotoxicity," Food Chem. Toxicol., vol. 138, Art. no. 111240, Apr. 2020, doi: 10.1016/j.fct.2020.111240.

[11] A. Ramachandran and H. Jaeschke, "A mitochondrial journey through acetaminophen hepatotoxicity," Food Chem. Toxicol., vol. 140, Art. no. 111282, Jun. 2020, doi: 10.1016/j.fct.2020.111282.

[12] H. Jaeschke and A. Ramachandran, "Central mechanisms of acetaminophen hepatotoxicity: mitochondrial dysfunction by protein adducts and oxidant stress," Drug Metab. Dispos., vol. 52, no. 8, pp. 712–721, Jul. 2024, doi: 10.1124/dmd. 123.001279.

[13] M. Yan, Y. Huo, S. Yin, and H. Hu, "Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions," Redox Biol., vol. 17, pp. 274–283, Jul. 2018, doi: 10.1016/j.redox.2018.04.019.

[14] J. Liao, Q. Lu, Z. Li, J. Li, Q. Zhao, and J. Li, "Acetaminophen-induced liver injury: molecular mechanism and treatments from natural products," Front. Pharmacol., vol. 14, Art. no. 1122632, 2023, doi: 10.3389/fphar. 2023.1122632.

[15] G. Luo, L. Huang, and Z. Zhang, "The molecular mechanisms of acetaminophen-induced hepatotoxicity and its potential therapeutic targets," Exp. Biol. Med., vol. 248, no. 5, pp. 412–424, May 2023, doi: 10.1177/15353702221147563.

[16] M. Mazer and J. Perrone, "Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management," J. Med. Toxicol., vol. 4, no. 1, pp. 2–6, Mar. 2008, doi: 10.1007/BF03160941.

[17] W. Y. Park, "Controversies in acetaminophen nephrotoxicity," Kidney Res. Clin. Pract., vol. 39, no. 1, pp. 4–6, Mar. 2020, doi: 10.23876/j.krcp.20.027.

[18] J. F. Newton, M. Yoshimoto, J. Bernstein, G. F. Rush, and J. B. Hook, "Acetaminophen nephrotoxicity in the rat. I. Strain differences in nephrotoxicity and metabolism," Toxicol. Appl. Pharmacol., vol. 69, no. 2, pp. 291–306, Jun. 1983, doi: 10.1016/0041-008X(83)90311-3.

[19] J. F. Newton, M. Yoshimoto, J. Bernstein, G. F. Rush, and J. B. Hook, "Acetaminophen nephrotoxicity in the rat. II. Strain differences in nephrotoxicity and metabolism of p-aminophenol," Toxicol. Appl. Pharmacol., vol. 69, no. 2, pp. 307–318, Jun. 1983, doi: 10.1016/0041-008X(83)90312-5.

[20] P. Blakely and B. R. McDonald, "Acute renal failure due to acetaminophen ingestion: a case report and review of the literature," J. Am. Soc. Nephrol., vol. 6, no. 1, pp. 48–53, Jul. 1995, doi: 10.1681/ASN.V6148.

[21] K. S. Gopi, A. G. Reddy, K. Jyothi, and B. A. Kumar, "Acetaminophen-induced hepato- and nephrotoxicity and amelioration by silymarin and Terminalia chebula in rats," Toxicol. Int., vol. 17, no. 2, pp. 64–66, 2010, doi: 10.4103/0971-6580.72672.

[22] Y. L. Zhao, G. D. Zhou, H. B. Yang, J. B. Wang, L. M. Shan, R. S. Li, and X. H. Xiao, "Rhein protects against acetaminophen-induced hepatic and renal toxicity," Food Chem. Toxicol., vol. 49, no. 8, pp. 1705–1710, Aug. 2011, doi: 10.1016/j.fct.2011.04.011.

[23] H. Safayhi, T. Mack, J. Sabieraj, M. I. Anazodo, L. R. Subramanian, and H. P. T. Ammon, "Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase," J. Pharmacol. Exp. Ther., vol. 261, no. 3, pp. 1143–1146, Jun. 1992, doi: 10.1016/S0022-3565(25)11130-0.

[24] M. Z. Siddiqui, "Boswellia serrata, a potential antiinflammatory agent: an overview," Indian J. Pharm. Sci., vol. 73, no. 3, pp. 255–261, May 2011, doi: 10.4103/0250-474X.93507.

[25] M. Abdel-Tawab, O. Werz, and M. Schubert-Zsilavecz, "Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data," Clin. Pharmacokinet., vol. 50, no. 6, pp. 349–369, Jun. 2011, doi: 10.2165/11586800-000000000-00000.

[26] D. Poeckel and O. Werz, "Boswellic acids: biological actions and molecular targets," Curr. Med. Chem., vol. 13, no. 28, pp. 3359–3369, 2006, doi: 10.2174/092986706779010333.

[27] N. K. Roy, D. Parama, K. Banik, D. Bordoloi, A. K. Devi, K. K. Thakur, G. Padmavathi, M. Shakibaei, L. Fan, G. Sethi, and A. B. Kunnumakkara, "An update on pharmacological potential of boswellic acids against chronic diseases," Int. J. Mol. Sci., vol. 20, no. 17, Art. no. 4101, Aug. 2019, doi: 10.3390/ijms20174101.

[28] E. A. Ragab, M. F. Abd El-Wahab, A. S. Doghish, R. M. Salama, N. Eissa, and S. F. Darwish, "The journey of boswellic acids from synthesis to pharmacological activities," Naunyn Schmiedebergs Arch. Pharmacol., vol. 397, no. 3, pp. 1477–1504, Mar. 2024, doi: 10.1007/s00210-023-02725-w.

[29] K. Sengupta, J. N. Kolla, A. V. Krishnaraju, N. Yalamanchili, C. V. Rao, T. Golakoti, S. Raychaudhuri, and S. P. Raychaudhuri, "Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract," Mol. Cell. Biochem., vol. 354, nos. 1–2, pp. 189–197, Aug. 2011, doi: 10.1007/s11010-011-0818-1.

[30] V. K. Alluri, S. Dodda, E. K. Kilari, T. Golakoti, and K. Sengupta, "Toxicological assessment of a standardized Boswellia serrata gum resin extract," Int. J. Toxicol., vol. 38, no. 5, pp. 423–435, Sep. 2019, doi: 10.1177/1091581819858069.

[31] S. Dodda, R. K. Madireddy, V. K. Alluri, T. Golakoti, and K. Sengupta, "Safety assessment of a novel water-soluble extract of Boswellia serrata gum resin: acute toxicity, 90-day sub-chronic toxicity, Ames' bacterial reverse mutation, and in vivo micronucleus assays," Toxicol. Mech. Methods, vol. 32, no. 5, pp. 362–372, Jun. 2022, doi: 10.1080/15376516.2021.2012545.

[32] H. M. Eltahir, M. A. Fawzy, E. M. Mohamed, M. A. Alrehany, A. M. Shehata, and M. M. Abouzied, "Antioxidant, anti-inflammatory and anti-fibrotic effects of Boswellia serrate gum resin in CCl4-induced hepatotoxicity," Exp. Ther. Med., vol. 19, no. 2, pp. 1313–1321, Feb. 2020, doi: 10.3892/etm.2019.8353.

[33] N. Monir, M. M. Saber, A. S. Awad, M. E. Elsherbiny, and H. F. Zaki, "Repression of inflammatory pathways with Boswellia for alleviation of liver injury after renal ischemia reperfusion," Life Sci., vol. 306, Art. no. 120799, Oct. 2022, doi: 10.1016/j.lfs.2022.120799.

[34] H. M. Eltahir, A.-G. S. Shalkami, A. M. Shehata, M. Almikhlafi, A. J. Aldhafiri, A. Alalawi, M. Albadrani, A. B. Mahmoud, and M. M. Abouzied, "Boswellia serrate gum resin mitigates renal toxicity: role of TNF-α, interleukins, TGF-β, and lipid peroxidation," Life, vol. 14, no. 12, Art. no. 1669, Dec. 2024, doi: 10.3390/life14121669.